BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for Agitation

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia Submitted protocol to FDA for TRANQUILITY In-Care pivotal Phase 3 trial for agitation associated with Alzheimer’s dementia Company to maintain IGALMI(TM) in the market without current commercial infrastructure NEW HAVEN, Conn., Sept. 19, 2024 (GLOBE NEWSWIRE) — — BioXcel […]

Multilingual Fentanyl Awareness Resources Released

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) — Today, the Addiction Policy Forum released new fentanyl awareness resources available in 12 languages to help increase knowledge of fentanyl-related overdose risks. The project is supported by the Cencora Impact Foundation and the Ethnic Communities Opioids Response Network – Missouri (ECORN-MO) to provide open-source, science-backed prevention materials

ValOre Partners with VRIFY to Leverage AI Mineral Targeting Platform to Accelerate Discovery Process

VANCOUVER, British Columbia, Sept. 19, 2024 (GLOBE NEWSWIRE) — ValOre Metals Corp. (“ValOre”; TSXâ?V: VO; OTCQB: KVLQF; Frankfurt: KEQ0, “the Company”) today announced a partnership with VRIFY which incorporates VRIFY’s cutting-edge Artificial Intelligence (“AI”) mineral targeting platform. This partnership aims to both accelerate and enhance the mineral discovery process by taking an unbiased data-driven approach

Gain Therapeutics to Present Preclinical GT-02287 Data in Parkinson’s Disease Models Including Two Late-Breakers at Neuroscience 2024

BETHESDA, Md., Sept. 19, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced presentations, including two late-breakers, at Neuroscience 2024 featuring preclinical data supporting development of GT-02287, the Company’s clinical stage

Tonix Pharmaceuticals Announces Issuance of U.S. Patent by the United States Patent and Trademark Office Covering the Intranasal Delivery of FDA-Approved Tosymra(R) to Treat Migraines

New patent expected to expire in 2030 Tosymra(R) (sumatriptan nasal spray) 10mg is indicated and marketed for the acute treatment of migraine in adults CHATHAM, N.J., Sept. 19, 2024 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates,

Solaris Reports 475m of 1.03% CuEq from Surface in New Drilling as Further Productivity Gains Drive Record 10km Drilled in August

QUITO, Ecuador, Sept. 19, 2024 (GLOBE NEWSWIRE) — Solaris Resources Inc. (TSX: SLS; NYSE: SLSR) (“Solaris” or the “Company”) is pleased to report assay results from its ongoing 60,000m 2024 drilling program that aims to target open extensions of mineralization while upgrading mineral resources and converting waste at its Warintza Project (“Warintza” or “the Project”)

Plug Power Launches an Equipment Lease Financing Platform – Plug is Targeting >$150 million from a Combination of Debt Leverage & Customer Financing Solutions

SLINGERLANDS, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, has announced the establishment of an equipment leasing platform and is targeting over $150 million in the near to mid-term. This platform is intended to enable Plug to access capital

CW Petroleum Corp (OTCQB: CWPE) Yahoo Finance Stock Quote Data from OTC Markets Not Functioning Properly for CWPE

Katy, Texas, Sept. 19, 2024 (GLOBE NEWSWIRE) — CW Petroleum Corp (OTCQB: CWPE) (the “Company”), a leading provider of Specialty Renewable and Hydrocarbon Motor Fuels, today announces to its investors and future investors it has had numerous discussions with OTC Markets regarding Yahoo Finance and Apple Stocks App powered by Yahoo Finance for providing inaccurate

FactSet Reports Results for Fourth Quarter 2024

Q4 GAAP revenues of $562.2 million, up 4.9% from Q4 2023. Organic Q4 ASV plus professional services of $2,272.8 million, up 4.8% year over year. Q4 GAAP operating margin of 22.7%, up approximately 110 bps year over year, and adjusted operating margin of 35.8%, up 240 bps from the prior year. Q4 GAAP diluted EPS

PyroGenesis Congratulates its Client EarthGrid on its Joint Venture with EnerTech to Deploy US$18B in Plasma-Powered Tunnel Boring Projects

MONTREAL, Sept. 19, 2024 (GLOBE NEWSWIRE) — PyroGenesis Canada Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to congratulate its client EarthGrid, which announced yesterday

Scroll to Top